<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>Current status of the management of hereditary breast and ovarian cancer in Asia: first report by the Asian BRCA consortium</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author(s)</strong></td>
<td>Nakamura, S; Kwong, A; Kim, SW; Iau, P; Patmasiriwat, P; Dofitas, R; Aryandono, T; Hu, Z; Huang, CS; Ginsburg, O; Muhammad, UR; Sarin, R; Teo, SH</td>
</tr>
<tr>
<td><strong>Citation</strong></td>
<td>The 2015 Global Breast Cancer Conference (GBCC 2015) and 4th International Breast Cancer Symposium (IBCS), Jeju Island, South Korea, 23-25 April 2015. In Abstracts Book, 2015, p. 340-341</td>
</tr>
<tr>
<td><strong>Issued Date</strong></td>
<td>2015</td>
</tr>
<tr>
<td><strong>URL</strong></td>
<td><a href="http://hdl.handle.net/10722/215350">http://hdl.handle.net/10722/215350</a></td>
</tr>
<tr>
<td><strong>Rights</strong></td>
<td>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
Current Status of the Management of Hereditary Breast and Ovarian Cancer in Asia: First Report by the Asian BRCA Consortium

Seigo Nakamura1, Ava Kwong2*, Sung-Won Kim3, Philip Iau4, Pimpicha Patmasiriwat5, Rodney Dofitas6, Teguh Aryandono7, Zhen Hu8, Chiun-Sheng Huang9, Ophira Ginsburg10, Muhammad Usman Rashid11, Rajiv Sarin12, Soo-Hwang Teo13

1Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Japan
2Department of Surgery, The University of Hong Kong, Hong Kong
3Department of Surgery, Seoul National University Bundang Hospital, Korea
4Department of Surgery, National University of Singapore, Singapore
5Department of Clinical Microscopy, Mahidol University, Thailand
6Department of Surgery, University of the Philippines Manila - Philippine General Hospital, Philippines
7Department of Surgery, Gadjah Mada University, Indonesia
8Department of Breast Surgery, Fudan University, China
9Department of Surgery, National Taiwan University Hospital, Taiwan
10Department of Medicine, University of Toronto, Canada
11Department of Basic Sciences Research, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Pakistan
12Department of Radiation Oncology and Genetics, Tata Memorial Center, India
13Department of Surgery, University Malaya Cancer Research Institute, Malaysia

Background/Purpose: BRCA1/2 mutation carriers possess an elevated lifetime risk for hereditary breast and ovarian cancer (HBOC), yet the availability of risk assessment and genetic testing for HBOC in Asians is far limited, thus limiting the chances for appropriate surveillance, clinical strategies and cancer management.

Methods: Current status of HBOC management in 14 Asian countries was reviewed. Data of genetic counseling and genetic testing uptake rates were collected, and were analyzed how economic factors, healthcare system, legal frameworks and cultural issues affect the genetic service availability in Asia.

Results: It was estimated that in 2012, of the 560,000 breast cancer patients in 14 Asian countries, only around 4,000 individuals were benefited from genetic counseling and 3,200 were tested, in which over 40% of the cases were from Korea. Economic factors
such as genetic service costs, and the lack of adoption into national healthcare systems (with the exception of Korea) are major barriers to genetic risk assessment in Asian countries. In addition, regional accredited laboratories, training programmes, and trained healthcare professionals are readily available only in half of the studied countries.

**Conclusion:** These limitations in healthcare system, combined with the lack of legal frameworks against genetic discrimination and lack of awareness among general public, remain the main challenges to HBOC management in Asia. The Asian BRCA (ABRCA) Consortium reports the current limitations in genetic counseling and testing for familial breast cancer in Asia, and urges the governments, healthcare sectors and researchers to address the disparities in HBOC management.